Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 2
July 15, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
-
REGULATORY Govt, Pharma Leaders to Meet in August for Drafting of “Comprehensive Strategy”
July 13, 2015
-
ORGANIZATION “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
-
REGULATORY MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
-
BUSINESS Sawai Gearing Up to Revise 3-Year Biz Plan after New Generic Target
July 8, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
-
BUSINESS Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
-
REGULATORY NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
-
ORGANIZATION FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
July 2, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
-
REGULATORY Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
-
TRENDS 3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
REGULATORY Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
-
TRENDS “80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
REGULATORY LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
-
REGULATORY HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
-
REGULATORY Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
-
REGULATORY LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…